Free Access
Med Sci (Paris)
Volume 29, Number 4, Avril 2013
Page(s) 425 - 429
Section M/S Revues
Published online 26 April 2013
  1. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice, in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008 ; 10 : R67. [CrossRef] [PubMed] [Google Scholar]
  2. Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxford) 2012 ; 51 : v22–v30. [CrossRef] [PubMed] [Google Scholar]
  3. Elias JA, Lee CG. IL-13 in asthma. The successful integration of lessons from mice and humans. Am J Respir Crit Care Med 2011 ; 183 : 957–958. [CrossRef] [PubMed] [Google Scholar]
  4. Sebzda E, Mariathasan S, Ohteki T, et al. Selection of the T cell repertoire. Annu Rev Immunol 1999 ; 17 : 829–874. [CrossRef] [PubMed] [Google Scholar]
  5. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012 ; 30 : 531–564. [CrossRef] [PubMed] [Google Scholar]
  6. Goodnow CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 1996 ; 93 : 2264–2271. [CrossRef] [Google Scholar]
  7. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989 ; 337 : 562–566. [CrossRef] [PubMed] [Google Scholar]
  8. Cambier JC, Gauld SB, Merrell KT, Vilen BJ. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat Rev Immunol 2007 ; 7 : 633–643. [CrossRef] [PubMed] [Google Scholar]
  9. Zagury D, Bernard J, Halbreich A, et al. One-year follow-up of vaccine therapy in HIV-infected immune-deficient individuals: a new strategy. J Acquir Immune Defic Syndr 1992 ; 5 : 676–681. [PubMed] [Google Scholar]
  10. Gringeri A, Musicco M, Hermans P, et al. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol 1999 ; 20 : 358–370. [CrossRef] [PubMed] [Google Scholar]
  11. Dalum I, Jensen MR, Hindersson P, et al. Breaking of B cell tolerance toward a highly conserved self protein. J Immunol 1996 ; 157 : 4796–4804. [PubMed] [Google Scholar]
  12. Dalum I, Butler DM, Jensen MR, et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 1999 ; 17 : 666–669. [CrossRef] [PubMed] [Google Scholar]
  13. Richard M, Grencis RK, Humphreys NE, et al. Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc Natl Acad Sci USA 2000 ; 97 : 767–772. [CrossRef] [Google Scholar]
  14. Khan WI, Richard M, Akiho H, et al. Modulation of intestinal muscle contraction by interleukin-9 (IL-9) or IL-9 neutralization: correlation with worm expulsion in murine nematode infections. Infect Immun 2003 ; 71 : 2430–2438. [CrossRef] [PubMed] [Google Scholar]
  15. Arendse B, Van Snick J, Brombacher F. IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses. J Immunol 2005 ; 174 : 2205–2211. [PubMed] [Google Scholar]
  16. Bizzini B, Drouet B, Zagury D, et al. Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer. Immunotherapy 2010 ; 2 : 347–365. [CrossRef] [PubMed] [Google Scholar]
  17. Zagury D, Le Buanec H, Mathian A, et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci USA 2009 ; 106 : 5294–5299. [CrossRef] [Google Scholar]
  18. Bensussan A, Bizzini B, Pouletty P, et al. Les kinoïdes : une nouvelle génération de vaccins thérapeutiques. Med Sci (Paris) 2008 ; 24 : 306–313. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  19. Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2006 ; 36 : 2868–2874. [CrossRef] [PubMed] [Google Scholar]
  20. Uyttenhove C, Marillier RG, Tacchini-Cottier F, et al. Amine-reactive OVA multimers for auto-vaccination against cytokines and other mediators: perspectives illustrated for GCP-2 in L. major infection. J Leukoc Biol 2011 ; 89 : 1001–1007. [CrossRef] [PubMed] [Google Scholar]
  21. Bachmann M, Hoffmann Rorher U, Kündig TM, et al. The influence of antigen organization on B cell responsiveness. Science 1993 ; 262 : 1448–1451. [CrossRef] [PubMed] [Google Scholar]
  22. Bachmann MF, Dyer MR. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov 2004 ; 3 : 81–88. [CrossRef] [PubMed] [Google Scholar]
  23. Jegerlehner A, Tissot A, Lechner F, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002 ; 20 : 3104–3112. [CrossRef] [PubMed] [Google Scholar]
  24. Sonderegger I, Rohn TA, Kurrer MO, et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 2006 ; 36 : 2849–2856. [CrossRef] [PubMed] [Google Scholar]
  25. Hertz M, Mahalingam S, Dalum I, et al. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J Immunol 2001 ; 167 : 3792–3799. [PubMed] [Google Scholar]
  26. Morimoto S, Kanno Y, Tanaka Y, et al. CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses. J Immunol 2000 ; 164 : 4097–4104. [PubMed] [Google Scholar]
  27. Ito T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 2005 ; 202 : 1213–1223. [CrossRef] [PubMed] [Google Scholar]
  28. Salek-Ardakani S, Song J, Halteman BS, et al. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med 2003 ; 198 : 315–324. [CrossRef] [PubMed] [Google Scholar]
  29. Lemaire MM, Vanhaudenarde A, Nizet Y, et al. Induction of autoantibodies against mouse soluble proteins after immunization with living cells presenting the autoantigen at the cell surface in fusion with a human type 2 transmembrane protein. J Immunol Methods 2011 ; 367 : 56–62. [CrossRef] [PubMed] [Google Scholar]
  30. Uyttenhove C, Sommereyns C, Theate I, et al. Anti-IL-17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis. Ann NY Acad Sci 2007 ; 1110 : 330–336. [CrossRef] [Google Scholar]
  31. Verbeke H, Struyf S, Berghmans N, et al. Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis. Cancer Lett 2011 ; 302 : 54–62. [CrossRef] [PubMed] [Google Scholar]
  32. Le Buanec H, Bensussan A, Bagot M, et al. Active and passive anticytokine immune therapies: current status and development. Adv Immunol 2012 ; 115 : 187–227. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.